InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
4
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-19.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by COLWILL BRUCE, Chief Financial Officer. Officer active across 1 company, notably InMed Pharmaceuticals Inc.. Cumulatively, 4 disclosures have been recorded. Split: 4 buys · 0 sell. Total volume traded: €25k. Activity tracked since 28 September 2021. The latest transaction was disclosed on 24 January 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations4 total
5,000 shares@ US$1.08770.074% mcap19.4% of flowCommon StockSEC:0001213900-22-003286:0
Ideal exit: 21 Oct 2022 (T+270)
5,000 shares@ US$1.087719.4% of flowCommon StockSEC:0001213900-22-003286
Ideal exit: 21 Oct 2022 (T+270)
5,000 shares@ US$1.76830.6% of flowCommon StockSEC:0001213900-21-050521
Ideal exit: 25 Jun 2022 (T+270)
5,000 shares@ US$1.7680.12% mcap30.6% of flowCommon StockSEC:0001213900-21-050521:0
Ideal exit: 25 Jun 2022 (T+270)
4 of 4 declarations
About COLWILL BRUCE
Bruce Colwill is the Chief Financial Officer of InMed Pharmaceuticals Inc. He is responsible for the financial management of the company, including budgeting, financial risk management, and regulatory compliance. Bruce plays a crucial role in the strategic direction of InMed, which focuses on developing cannabis-based therapies. His expertise in corporate finance is essential to support growth and innovation within the company.
